Celldex Barzolvolimab Fails PN Phase 2: AD Readout in Doubt

Celldex Therapeutics (CLDX) discontinued development of barzolvolimab in prurigo nodularis after the drug missed its primary and key secondary endpoints in a Phase 2 trial, despite achieving what the company called “profound systemic mast cell depletion.” The news, reported after market close on July 21, sent shares down roughly 7% in extended trading before recovering to close at $35.42 on July 23 with volume of 856,000 shares.

What the trial showed

Barzolvolimab is an anti-KIT monoclonal antibody designed to deplete mast cells. The Phase 2 trial tested whether that depletion would translate into clinical benefit for prurigo nodularis, a chronic skin disease characterized by intense itching and hard nodules.

The answer was no. The 140-patient trial missed its primary endpoint: the proportion of patients achieving a 4-point or greater improvement on the WI-NRS (Worst Itch Numeric Rating Scale) from baseline to Week 12. The miss was not close (p=0.868 for the 150mg dose; p=0.428 for the 300mg dose). Key secondary endpoints also missed. Barzolvolimab produced significant reductions in serum tryptase, confirming mast cells were being depleted as intended. But clinical outcomes, including itch severity and skin lesion clearance, were no different from placebo. Celldex reported no improvement through extended treatment to Week 24.

The disconnect matters. If mast cell depletion does not improve symptoms, it raises the question of whether mast cells are actually a primary driver of the disease, or just a downstream participant. For a framework on reading clinical trial endpoints and spotting a miss before the market does, see our guide to reading a clinical trial press release.

Why the atopic dermatitis readout is now in doubt

Celldex has a separate Phase 2 trial of barzolvolimab in atopic dermatitis expected to read out in Q4 2026. TD Cowen noted the PN failure “somewhat weakens the argument” for the AD program because both diseases share components of pruritic pathology hypothesized to be mast-cell-driven.

The risk is read-across: if mast cell depletion does not work in one pruritic skin disease, investors will discount the odds it works in another. Celldex was “disappointed” the study did not confirm a promising signal from an earlier intravenous Phase 1b trial, and TD Cowen flagged the switch from IV to subcutaneous delivery as a factor.

What remains: the CSU program

The core thesis now rests on Phase 3 data in chronic spontaneous urticaria (CSU) and cold urticaria, expected September through October 2026. Barzolvolimab has shown strong efficacy and a tolerable safety profile in CSU, where mast cells have a more established role. Analysts view this as the thesis-defining readout.

Wells Fargo maintained an Overweight rating but lowered its price target to $48. Morgan Stanley also maintained Overweight with a $40 target. The analyst consensus is that CSU, not PN or AD, determines whether barzolvolimab becomes a commercial product.

One safety signal worth monitoring: Celldex disclosed an investigator’s diagnosis of aseptic meningitis as a serious adverse event, though the company “strongly disagreed” with the diagnosis and suggested it may have been a viral neuroinflammatory event. This is not confirmed but adds uncertainty.

What to watch next

The CSU Phase 3 readout in September or October is the next major catalyst. If positive, barzolvolimab still has a path to market in a well-established mast-cell-driven indication. If the AD readout follows in Q4 and also disappoints, the mast cell depletion thesis narrows significantly.

For Celldex, the stock at $35.42 is telling you the market still believes in CSU. The PN failure is a setback, but not the end of the program.

What It Means for the Trade

The PN miss deserves more analytical respect than a 7% dip-and-recover suggests, because it is a rare event: a clean, mechanistically decisive negative trial. Barzolvolimab did exactly what it was designed to do — the serum tryptase drops confirm profound mast cell depletion — and the clinical endpoints came back identical to placebo, with p-values (0.868 and 0.428) that aren’t borderline. In drug development, a mechanism-engaged trial with zero clinical separation is the strongest possible evidence that the target isn’t the driver in that disease. That is different from a trial that missed for power or design reasons, and it means the read-across discount on atopic dermatitis is rational, not skittish.

The market’s structure for the next two quarters is now legible: CSU (Phase 3, September-October) is the thesis, and everything else is optionality priced at a discount. The reason the stock recovered to $35.42 and held its analyst ratings (Wells Fargo Overweight $48, Morgan Stanley Overweight $40) is that CSU has a defensible mechanistic foundation — chronic urticaria is the one indication where mast cells are unambiguously central, and barzolvolimab’s demonstrated depletion plus existing CSU efficacy data gives the program a genuine prior. The PN failure actually sharpens the investment question: it is no longer “how big is the mast-cell platform,” it is “does mast-cell depletion work where mast cells are proven drivers.” CSU answers that directly.

Mechanism and Program Context

The biology explains why the diseases split. Prurigo nodularis is a chronic itch-scratch cycle disease where the itch signal is driven by a mix of neural sensitization, type 2 inflammation (IL-4/IL-13 — the pathway Dupixent and Nemluvio target with demonstrated success in PN), and mast cell mediators. Mast cells are participants, not instigators; deplete them completely and the IL-13-driven pruritus persists. The same logic applies with more uncertainty to atopic dermatitis — a type 2-dominant disease where mast cells contribute but established cytokine blockade already works — which is why the AD readout’s prior dropped even though it wasn’t tested. CSU is the other order of disease: histamine and mast cell activation are the proximate drivers of wheals and flares, which is why antihistamines (the standard of care, dosed up to 4x for refractory patients) work at all, and why a drug that removes the mast cell entirely attacks the disease at its root.

The delivery-switch question TD Cowen flagged deserves attention for the AD trial handicapping: the promising Phase 1b PN signal was intravenous, the failed Phase 2 was subcutaneous, and if exposure at the skin compartment differed meaningfully between routes, some of the PN miss could be pharmacokinetic rather than mechanistic. That is a charitable read the CSU data will implicitly test — CSU trials have their own route history to check against.

Risks and What Could Go Wrong

1. The CSU Phase 3 misses or lands ambiguous — with PN dead and AD discounted, there is no third mast-cell indication carrying value; a CSU miss is a thesis-ending event, not a setback.
2. The aseptic meningitis report, whatever its final adjudication, sits in the safety database the FDA will review; a neurologic signal on a mast-cell depleter complicates any label narrative even if disputed.
3. The AD readout in Q4 also misses: the mast-cell depletion thesis narrows to one approved-competition-heavy indication and the platform premium evaporates from the multiple.
4. Competitive crowding in CSU: omalizumab’s long dominance and the newer entrants give barzolvolimab a contested launch even with clean Phase 3 data.

Position read: CLDX into the September-October CSU readout is a single-binary position and should be sized as one — the analysts’ Overweight ratings all say the same thing the price does: everything now rides on urticaria.

Source: Celldex press release via GlobeNewswire | Fierce Biotech